CWP
TCRT icon

CFM Wealth Partners’s Alaunos Therapeutics TCRT Stock Holding History

CFM Wealth Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10
Closed -$4K – 420
2020
Q2 		$4K Hold
10
– – ﹤0.01% 448
2020
Q1 		$4K Hold
10
– – ﹤0.01% 486
2019
Q4 		$7K Buy
+10
New +$6.88K ﹤0.01% 441

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CFM Wealth Partners's TCRT Position: Q3 2020 in Review

CFM Wealth Partners sold out of Alaunos Therapeutics (TCRT) in Q3 2020, closing a stake of 10 shares — an estimated $4K sold.

CFM Wealth Partners first reported a position in TCRT in Q4 2019 and held it in 3 quarters. The position peaked at $7K in Q4 2019. 154 funds tracked by Wall St. Rank hold TCRT as of Q3 2020.

  • CFM Wealth Partners reported no remaining Alaunos Therapeutics position as of Q3 2020 after selling out during the quarter.
  • CFM Wealth Partners sold 10 Alaunos Therapeutics shares in Q3 2020, an estimated $4K.
  • CFM Wealth Partners first reported a position in Alaunos Therapeutics in Q4 2019 and held it in 3 quarters.
  • CFM Wealth Partners's Alaunos Therapeutics position peaked at $7K in Q4 2019.
  • 154 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2020.

Based on CFM Wealth Partners's 13F filing for Q3 2020, filed 10 Nov 2020.